Table 1. Summary of Receiver Operating Characteristic (ROC) analyses of clinical factors and early-phase circulating miRNAs in predicting HCC recurrence after liver transplantation.

	ROC analysis of 62 HCC patients
	Sensitivity	Specificity	AUC (95% CI)	P value
Clinical factors
Milan Criteria (Beyond vs within)	77.8%	67.9%	0.729 (0.553 – 0.904)	0.029*
UCSF criteria (Beyond vs within)	66.7%	79.2%	0.730 (0.538 – 0.921)	0.029*
pTNM stage (Advanced vs early)	100%	56.6%	0.717 (0.571 – 0.863)	0.049*
Pre-OT AFP level (≥20ng/ml vs <20ng/ml)	55.6%	58.5%	0.570 (0.366 – 0.774)	0.503
Tumor size (≥5cm vs <5cm)	0%	5.7%	0.472 (0.264 – 0.679)	0.798
Vascular permeation (Yes vs no)	62.5%	26.9%	0.678 (0.469 – 0.887)	0.108
Graft weight to recipient ESLV (≤60% vs > 60%)	88.9%	69.8%	0.595 (0.411 – 0.780)	0.363
Type of transplant (LDLT vs DDLT)	88.9%	83.0%	0.529 (0.330 – 0.728)	0.780
Tumor number (>3 vs ≤3)	44.4%	0.151%	0.647 (0.433 – 0.860)	0.162
Differentiation (Poor vs well)	14.3%	6.0%	0.541 (0.301 – 0.782)	0.782
Early-phase circulating miRNAs
miR-148a (High vs Low)	88.9%	56.6%	0.727 (0.570 – 0.885)	0.030*
miR-1246 (High vs Low)	88.9%	66.0%	0.775 (0.626 – 0.923)	0.009**
miR-1290 (High vs Low)	66.7%	73.6%	0.701 (0.509 – 0.894)	0.055
miR-148a + miR-1246 (Yes vs no)	88.9%	79.2%	0.841 (0.704 – 0.978)	0.001**

^*p<0.05;

^**p<0.01.